PHAR News and Press, Pharming Group N.V. From 09/28/22

Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib Canada NewsWire The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for len...

CEO of Pharming to present at H.C. Wainwright 24th Annual Global Investment Conference PR Newswire LEIDEN, The Netherlands , Sept. 7, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that its Chief E...

Orchard Therapeutics has become interesting after its 78% dip plus the fact that a large investment fund quadrupled its position in the stock. The company has commercialized gene therapy to combat MDL, which inflicts children. A competitive analysis reveals the strength of the U.K...

Pharming Group N.V. (PHGUF) First Half 2022 Earnings Conference Call August 04, 2022 7:30 AM ET Company Participants Sijmen de Vries – Chief Executive Officer Anurag Relan – Chief Medical Officer Jeroen Wakkerman – Chief Financial Officer ...

The following slide deck was published by Pharming Group N.V. in conjunction with their 2022 Q2 earnings call. For further details see: Pharming Group N.V. 2022 Q2 - Results - Earnings Call Presentation

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency Canada NewsWire Implemented by the Centers for Disease Control and Prevention, the diagnosis code will accurately identify US patients with APDS, supporting care and research efforts ...

A committee of the European Medicines Agency (EMA) granted accelerated assessment for Pharming's ( NASDAQ: PHAR ) potential application seeking approval of leniolisib to treat patients aged 12 years and older with activated phosphoinositide 3-kinase (PI3K) delta syndr...

Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS Canada NewsWire EMA accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days ...

Pharming Group N.V. (PHGUF) Q1 2022 Earnings Conference Call May 12, 2022, 07:30 AM ET Company Participants Sijmen de Vries - CEO Jeroen Wakkerman - CFO Anurag Relan - Chief Medical Officer Conference Call Participants Joe Pantginis - H.C. Wainright Hartaj Singh - Oppenheimer & Co. Christ...

Pharming Group (NASDAQ:PHAR) said the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) granted promising innovative medicine (PIM) designation to leniolisib to treat activated phosphoinositide 3-kinase delta syndrome (APDS), a rare immunodeficiency disease. The comp...